Loading stock data…
$5.35
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States.
CNS Pharmaceuticals, Inc. in the Healthcare sector is trading at $5.35 with a market capitalization of $8M. Wall Street consensus targets $10.00 (1 analysts), implying a +86.9% move over the next 12 months. The stock is currently 49% below its 52-week high of $10.54, remaining 15.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.70M↑ | -$4.98M↑ | -$5.99M↓ | -$3.25M↓ | -$2.41M |
| Net Income | -$2.59M↑ | -$4.94M↑ | -$5.96M↓ | -$3.22M↓ | -$2.38M |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical ...